Martin Shkreli: Big Pharma's Blind Spot, Betting Against Quantum & What Prison Taught Him
Former hedge fund manager and pharmaceutical executive Martin Shkreli joins the show to discuss why he is shorting quantum computing and why he believes the technology lacks commercial viability. He details the market inefficiencies in big pharma that allowed him to acquire and repurpose blockbuster drugs, and pushes back against claims that AI will revolutionize drug discovery. Finally, Shkreli reflects on the psychology of intellectual arrogance, his interactions with figures like Sam Bankman-Fried, and the personal lessons learned while serving time in federal prison.
- Dario Amodei predicts artificial intelligence will cure most human diseases in the coming years, while Martin Shkreli predicts zero clinically meaningful AI-discovered drugs will reach the market over the next decade. Read →
- Martin Shkreli bought the rights to Sparsentan from Bristol Myers Squibb for $2 million; today, the public company holding that drug is worth $6 billion. Read →
- Foundational intelligence will commoditize like the early internet, leaving value in the hands of consumers and operational businesses rather than raw model hosts. Read →
- Quantum computers operate at clock speeds measured in hundreds or thousands of hertz, whereas classical silicon chips run at multiple gigahertz. Read →
- Martin Shkreli predicts Nvidia flagships like the H100 and B200 will sit in the scrap heap within twenty years, replaced by optical architectures. Read →